[go: up one dir, main page]

JP2009510182A - シクリトールリンカーポリマー抱合体 - Google Patents

シクリトールリンカーポリマー抱合体 Download PDF

Info

Publication number
JP2009510182A
JP2009510182A JP2008524213A JP2008524213A JP2009510182A JP 2009510182 A JP2009510182 A JP 2009510182A JP 2008524213 A JP2008524213 A JP 2008524213A JP 2008524213 A JP2008524213 A JP 2008524213A JP 2009510182 A JP2009510182 A JP 2009510182A
Authority
JP
Japan
Prior art keywords
group
polymer
compound
biologically active
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008524213A
Other languages
English (en)
Japanese (ja)
Inventor
ターナー，デイビツド・アイ
カリアス，ペリー
クツク，ゲイリー・ピー
シマ，デイビツド・テイー
Original Assignee
（オーエスアイ）アイテツク・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by （オーエスアイ）アイテツク・インコーポレーテツド filed Critical （オーエスアイ）アイテツク・インコーポレーテツド
Publication of JP2009510182A publication Critical patent/JP2009510182A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
JP2008524213A 2005-07-28 2006-07-27 シクリトールリンカーポリマー抱合体 Pending JP2009510182A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70313305P 2005-07-28 2005-07-28
PCT/US2006/029503 WO2007016380A2 (fr) 2005-07-28 2006-07-27 Dispositifs et methodes d'execution de procedures sur un sein

Publications (1)

Publication Number Publication Date
JP2009510182A true JP2009510182A (ja) 2009-03-12

Family

ID=37451164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008524213A Pending JP2009510182A (ja) 2005-07-28 2006-07-27 シクリトールリンカーポリマー抱合体

Country Status (3)

Country Link
EP (1) EP1912676A2 (fr)
JP (1) JP2009510182A (fr)
WO (1) WO2007016380A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011055751A (ja) * 2009-09-09 2011-03-24 Tokyo Univ Of Agriculture & Technology デンドリマー修飾磁気微粒子の製造方法
JP2015509986A (ja) * 2012-03-16 2015-04-02 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
WO2016063957A1 (fr) * 2014-10-22 2016-04-28 スガイ化学工業株式会社 Dérivé de décaline et procédé de production associé

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791278C (fr) 2010-02-25 2015-11-24 The Johns Hopkins University Delivrance prolongee d'agents therapeutiques a un compartiment oculaire
US10307372B2 (en) 2010-09-10 2019-06-04 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
RU2598627C2 (ru) 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки
CA2867381C (fr) 2012-03-16 2016-09-20 The Johns Hopkins University Formulations a liberation controlee pour l'administration d'inhibiteurs du hif-1
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
JP6392209B2 (ja) 2012-05-04 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
DK2906246T3 (da) 2012-10-11 2023-09-04 Ascendis Pharma Ophthalmology Div A/S VEGF-neutraliserende prodrugs omfattende ranibizumab til behandling af okulære tilstande, der er kendetegnet ved okulær neovaskularisering
CN103830741B (zh) * 2012-11-27 2019-02-19 杨子剑 含有陶扎色替类似物结构的化合物以及制备方法和用途
CN103848901A (zh) * 2012-11-28 2014-06-11 杨子剑 含有万古霉素结构的新化合物以及制备方法和用途
CN103848894A (zh) * 2012-11-30 2014-06-11 杨子剑 含有达托霉素结构的新化合物以及制备方法和用途
CN103897041A (zh) * 2012-12-24 2014-07-02 杨子剑 含有万古霉素结构的新化合物以及制备方法和用途
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
WO2015127389A1 (fr) 2014-02-23 2015-08-27 The Johns Hopkins University Formulations de lavement hypotonique et méthodes d'utilisation
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089419A1 (fr) * 2003-04-04 2004-10-21 The University Of Tokyo Structure de membrane lipidique comportant un anticorps monoclonal anti-mt-mmp
JP2005508299A (ja) * 2001-06-21 2005-03-31 ジェネンテック・インコーポレーテッド 徐放性組成物
JP2005516033A (ja) * 2002-01-23 2005-06-02 イマークス セラピューティクス、インコーポレイテッド 診断および治療で使用する新規な標的組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021440A1 (fr) * 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Procedes pour accroitre la biodisponibilite d'agents ayant une activite biologique
RU2177950C2 (ru) * 1996-10-25 2002-01-10 Нексстар Фармасьютикалз, Инк. Комплексы нуклеиновых кислот - лигандов сосудистого эндотелиального фактора роста (vegf)
CN101273051B (zh) * 2003-04-13 2012-04-18 安龙制药公司 聚合寡核苷酸前体药物
US20050260153A1 (en) * 2004-04-13 2005-11-24 Pericles Calias Facilitation of iontophoresis using charged moieties

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508299A (ja) * 2001-06-21 2005-03-31 ジェネンテック・インコーポレーテッド 徐放性組成物
JP2005516033A (ja) * 2002-01-23 2005-06-02 イマークス セラピューティクス、インコーポレイテッド 診断および治療で使用する新規な標的組成物
WO2004089419A1 (fr) * 2003-04-04 2004-10-21 The University Of Tokyo Structure de membrane lipidique comportant un anticorps monoclonal anti-mt-mmp

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011055751A (ja) * 2009-09-09 2011-03-24 Tokyo Univ Of Agriculture & Technology デンドリマー修飾磁気微粒子の製造方法
JP2015509986A (ja) * 2012-03-16 2015-04-02 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
JP2017125075A (ja) * 2012-03-16 2017-07-20 ザ・ジョンズ・ホプキンス・ユニバーシティー 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
WO2016063957A1 (fr) * 2014-10-22 2016-04-28 スガイ化学工業株式会社 Dérivé de décaline et procédé de production associé
JPWO2016063957A1 (ja) * 2014-10-22 2017-08-03 スガイ化学工業株式会社 デカリン誘導体及びその製造方法

Also Published As

Publication number Publication date
WO2007016380A3 (fr) 2007-08-16
WO2007016380A2 (fr) 2007-02-08
EP1912676A2 (fr) 2008-04-23

Similar Documents

Publication Publication Date Title
JP2009510182A (ja) シクリトールリンカーポリマー抱合体
JP7323453B2 (ja) トレースレスリンカーを含む持続放出送達システム
JP4137184B2 (ja) 薬物複合体の製造方法
EP0916348B1 (fr) complexes médicamenteux alykldextrane-polyalcool
CN102172405B (zh) 多支链聚合物的药物前体
JP5881254B2 (ja) 自己免疫疾患およびその他の疾患の治療のための組成物および方法
JP5687752B2 (ja) オリゴマー−プロテアーゼ阻害剤複合体
CZ292775B6 (cs) Fyziologicky aktivní konjugát polyethylenglykol-interferon alfa, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje
TW201221132A (en) Cyclodextrin-based polymers for therapeutics delivery
JP2002512982A (ja) Ｐｅｇ−ｌｈｒｈアナログ複合体
LT3174B (en) Polyethylene glycol -interferon conjugates
CN102781478A (zh) 用于细胞内靶向增殖和蛋白质合成的聚阴离子多价大分子
CN118108876A (zh) 透明质酸衍生物、药物组合物和透明质酸衍生物-药物结合体
AU2020360397A1 (en) Protein-macromolecule conjugates and methods of use thereof
KR20240091157A (ko) ε-폴리-L-라이신을 기반으로 하는 약물 접합체, 이의 중간체 및 이의 적용
WO2017083659A1 (fr) Conjugués de nanoparticules polymères biodégradables et leur utilisation
JP2012530069A (ja) プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
CA3215405A1 (fr) Conjugues proteine-macromolecule et leurs methodes d'utilisation
RU2772690C2 (ru) Системы доставки с замедленным высвобождением, содержащие бесследные линкеры
WO2024220978A1 (fr) Hydrogels dégradables par programmation pour libération moléculaire fonctionnelle
WO2022069768A1 (fr) Nouvelles combinaisons de composés de bore et d'adjuvants pour le traitement d'états pathophysiologiques et du cancer et pour la régénération musculaire
Fernandez-Megia Synthesis of multi-functional dendrimers for targeted delivery of nucleic acids
MXPA06003108A (en) Multi-arm polymer prodrugs

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120207